Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: A case series

Lisa M. Morris, Hal A. Lewis, Lynn A. Cornelius, David Y. Chen, Ilana S. Rosman

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Checkpoint inhibitors have been revolutionary in the treatment of metastatic melanoma, non-small-cell lung cancer, and renal cell carcinoma. By restricting negative feedback of T-cells, checkpoint inhibitors allow the immune system to identify and destroy malignant cells. This enhanced immune response is efficacious in the treatment of the aforementioned malignancies; however, it may lead to immune-related adverse events. Bullous pemphigoid (BP) is a well-documented cutaneous adverse reaction of checkpoint inhibitors, with a majority of cases reporting an eosinophil-predominant or mixed inflammatory infiltrate. We report two cases of neutrophil-predominant BP presenting in patients on checkpoint inhibitors.

Original languageEnglish
JournalJournal of cutaneous pathology
DOIs
StateAccepted/In press - Jan 1 2020

Keywords

  • bullous pemphigoid
  • immune checkpoint inhibitors
  • immune-related adverse events
  • neutrophil

Fingerprint

Dive into the research topics of 'Neutrophil-predominant bullous pemphigoid induced by checkpoint inhibitors: A case series'. Together they form a unique fingerprint.

Cite this